SCHEMBL315410

SCHEMBL315410

CCOC(=O)Cn1nccn1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.49
PKM P14618 1/20 0.49
ATM Q13315 1/20 0.49
GSK3A P49840 1/20 0.48
GSK3B P49841 1/20 0.48
MAPK1 P28482 2/20 0.44
MGAM O43451 1/20 0.44
GAA P10253 1/20 0.44
SI P14410 1/20 0.44
MGAM2 Q2M2H8 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
ALDH1A1 P00352 5/20 0.43
PIN1 Q13526 1/20 0.43
PIN4 Q9Y237 1/20 0.43
TSHR P16473 1/20 0.43
HTT P42858 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ELANE P08246 1/20 0.42
TRPA1 O75762 1/20 0.41
MAPT P10636 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL333146 0.77 POLB (0.54) HSD17B10PKMATMGSK3AGSK3B
SCHEMBL16586833 0.75 NPSR1 (0.47) HSD17B10PKMGAASMN1; SMN2ALDH1A1
SCHEMBL1093819 0.75 GSK3A (0.44) HSD17B10GSK3AGSK3BMAPK1MGAM
SCHEMBL28604654 0.72 HSD17B10 (0.54) HSD17B10PKMATMGSK3AGSK3B
SCHEMBL2823777 0.72 MAPK1 (0.51) HSD17B10GSK3AGSK3BMAPK1GAA
SCHEMBL6962065 0.72 ALDH1A1 (0.57) HSD17B10PKMATMMAPK1GAA
SCHEMBL22824510 0.71 TDP1 (0.41)
SCHEMBL5795696 0.71 ALDH1A1 (0.42) HSD17B10GSK3AGSK3BMGAMGAA
SCHEMBL11110430 0.71 GSK3A (0.48) HSD17B10PKMATMGSK3AGSK3B
SCHEMBL7206290 0.71 MAPK1 (0.49) HSD17B10GSK3AGSK3BMAPK1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025051214-A1 AROMATIC HETEROCYCLIC COMPOUND AND PREPARATION METHOD THEREFOR 上海翊石医药科技有限公司 2025-03-13 WO disclosed
US-10301289-B2 Method for the preparation of triazole compounds BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2019-05-28 US disclosed
US-20180282331-A1 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS WOCKHARDT LIMITED (IN) 2018-10-04 US disclosed
WO-2017081615-A1 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS WOCKHARDT LIMITED (IN) 2017-05-18 WO disclosed
US-20150087827-A1 METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS BAYER PHARMA AKTIENGESELLSCAFT (DE) 2015-03-26 US disclosed
US-20150087827-A1 METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS BAYER PHARMA AKTIENGESELLSCAFT (DE) 2015-03-26 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-8093400-B2 Compounds useful in therapy PFIZER INC. (US) 2012-01-10 US disclosed
US-20100317652-A1 Compounds Useful In Therapy PFIZER INC 2010-12-16 US disclosed
WO-2005063754-A1 TRIAZOLE DERIVATIVES AS VASOPRESSIN ANTAGONISTS PFIZER LIMITED (GB) 2005-07-14 WO disclosed
WO-2005000841-A1 PREPARATION OF N2-ALKYLATED 1,2,3-TRIAZOLES WARNER-LAMBERT COMPANY LLC (US) 2005-01-06 WO disclosed
US-20040266848-A1 Preparation of N2-alkylated 1,2,3-triazoles HADD MARK ALLEN (US) 2004-12-30 US disclosed
EP-1490060-A1 ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2004-12-29 EP disclosed
CN-1558897-A oral antidiabetic agent ����-�����ع�˾ 2004-12-29 CN disclosed
US-6696474-B2 SUCH AS 8-(5-METHYL-2-PHENYL-OXAZOL-4-YL)-2-PYRROL-1-YL-OCT-4-YNOIC ACID; NONINSULIN DEPENDENT DIABETES MELLITUS WARNER LAMBERT CO. LLC. 2004-02-24 US disclosed
US-20030220381-A1 ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY, LLC 2003-11-27 US disclosed
WO-2003082276-A1 ANTIDIABETIC AGENTS WARNER-LAMBERT COMPANY LLC (US) 2003-10-09 WO disclosed
CN-1031133-C Pyrazolotriazole derivatives YAMANOUCHI PHARMA CO LTD (JP) 1996-02-28 CN disclosed
CN-1069978-A Pyrazolotriazole derivatives YAMANOUCHI PHARMA CO LTD (JP) 1993-03-17 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040266848-A1 Preparation of N2-alkylated 1,2,3-triazoles PPARA, PPARG, PPARD HSD17B10 1909/4885PKM 1227/4885ATM 2408/4885
US-20030220381-A1 ANTIDIABETIC AGENTS GPR119, GCKR, GLP1R HSD17B10 897/4885PKM 226/4885ATM 3074/4885
US-10301289-B2 Method for the preparation of triazole compounds CYP4B1, BRI3BP, BRD4 HSD17B10 3597/4885PKM 172/4885ATM 2429/4885
US-20150087827-A1 METHOD FOR THE PREPARATION OF TRIAZOLE COMPOUNDS CYP4B1, BRI3BP, BRD4 HSD17B10 3597/4885PKM 172/4885ATM 2429/4885
US-20180282331-A1 7-Oxo -6-(sulfooxy)- 1,6-diazabicyclo [3.2.1] octane containing compounds and their use in treatment of bacterial infections (changed by PCT to: 7-OXO -6-(SULFOOXY)- 1,6-DIAZABICYCLO [3.2.1] OCTANE CONTAINING COMPOUNDS AND THEIR USE IN TREATMENT OF BACTERIAL INFECTIONS TST, THPO, STS HSD17B10 1728/4885PKM 3431/4885ATM 2354/4885
US-20100317652-A1 Compounds Useful In Therapy AVPR1A, AVPR1B, AVPR2 HSD17B10 2776/4885PKM 1270/4885ATM 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.